Ernst & Young

News

The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.

Digital

Underinvestment in medical technology could threaten growth in the sector, according to a report by Ernst & Young (EY).

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Ernst &amp; Young